Literature DB >> 21847459

Berardinelli Seip syndrome with insulin-resistant diabetes mellitus and stroke in an infant.

C K Indumathi1, S Lewin, Vageesh Ayyar.   

Abstract

Berardinelli Seip congenital lipodystrophy (BSCL) is a rare metabolic disorder characterized by severe generalized lipodystrophy, insulin resistance, and dyslipedemia since infancy, and onset of overt diabetes mellitus in adolescence. Here we report a 5-month-old infant with clinical and metabolic manifestations of Berardinelli Seip syndrome including overt diabetes mellitus and stroke, which are very rare at this age.

Entities:  

Keywords:  Berardinelli Seip syndrome; diabetes mellitus; dyslipedemia; infancy; stroke

Year:  2011        PMID: 21847459      PMCID: PMC3152188          DOI: 10.4103/2230-8210.83054

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN: 2230-9500


INTRODUCTION

Berardinelli Seip congenital lipodystrophy is a rare autosomal recessive disease characterized by generalized absence of fat since birth and severe metabolic derangements such as severe insulin resistance, hyperglycemia, diabetes mellitus, and dyslipidemia (especially hypertriglyceridemia and low HDL). Diabetes mellitus generally develops during second and third decade. We describe a 5-month-old infant with BSCL presenting with diabetes mellitus.

CASE REPORT

A 5-month-old male infant was admitted with the history of progressive abdominal distension since one and a half months. He was a second baby born out of second -degree consanguinity. Birth weight was 2.5 kg. Antenatal and neonatal periods were uneventful. There was no history of polyuria, increased thirst or fast breathing. Elder sibling was 4-year-old male and doing well. On examination, weight was 5.2 kg. (3rd centile) and height was 63 cm (25th centile). Blood pressure was 90/60 mm of mercury. Baby had generalized absence of fat including buccal pad of fat (empty cheeks sign). There were dysmorphic features such as triangular face, low anterior hair line, depressed nose, large protruding tongue, long fingers and toes, large hands and feet, prominent veins over hands and feet and, excessive hair over thighs and legs with muscular hypertrophy [Figures 1 and 2]. There was no acanthosis nigricans. Per abdominal examination revealed massive hepatomegaly of 9 cm. [Figure 1], which was firm in consistency, and splenomegaly of 2 cm. Development was appropriate for age. Hearing was normal.
Figure 1

Clinical photograph revealing triangular face, depressed nose, empty cheeks, large protruding tongue, hepatomegaly, and prominent veins over hands and feet

Figure 2

Clinical photograph revealing excessive hair over thighs and legs with muscular hypertrophy

Clinical photograph revealing triangular face, depressed nose, empty cheeks, large protruding tongue, hepatomegaly, and prominent veins over hands and feet Clinical photograph revealing excessive hair over thighs and legs with muscular hypertrophy Investigations: lipid profile-cholesterol-119 mg/dl (114-203 mg/dl), HDL-<10 mg/dl (40-60 mg/dl), LDL-34 mg/dl (<130 mg/dl), triglycerides-1391 mg/dl (29-99 mg/dl), RBS 400 mg/dl. Frequent monitoring of blood glucose revealed persistent hyperglycemia (300-415 mg mg/dl). Serum insulin was elevated to 44 μIU/Ml (normal upto-23 μIU/Ml) suggesting insulin resistance and simultaneous glucose was 300 mg/dl. Liver function test was normal except mild elevation of AST and ALT. Urine ketone bodies were negative. X-ray of wrist revealed normal bone age. Echocardiogram was normal. Liver biopsy revealed extensive steatosis involving 95% of parenchyma with marked fibrosis with a fibrotic score of 3/4. Leptin estimation and genetic analysis could not be done because of lack of resources. Baby was started on NPH insulin (H insulotard) 1 unit twice daily and omega 3 fatty acids (decosa hexanoic acid and eicosapentaenoic acid) to control hyper triglyceridenemia. After a month, blood glucose was under control. Three months later, baby was readmitted with left-sided hemiplegia. CT brain revealed infarction in right middle cerebral artery territory. Child was started on aspirin. Presently child is 3-year old and weighing 12 kg. He is requiring two units of insulotard twice daily. Blood glucose is maintained between 100 and 150 mg/dl. His motor power in left upper and lower limb is 4/5. Mile stones are near normal except speech delay. Triglyceride has come down from 1391 mg/dl to 800 mg/dl.

DISCUSSION

Berardinelli Seip congenital lipodystrophy is a rare autosomal recessive metabolic syndrome with a prevalence of less than 1 case in 12 million and 200 cases have been reported so far.[1] Berardinelli first described the syndrome in 1954 and later confirmed by Seip in 1959. BSCL is linked to two genetic loci, on chromosomes 9q34 (AGPAT2 gene) and 11q13 (BSCL2 gene).[1-3] BSCL is characterized by generalized loss of subcutaneous fat (including buccal pad of fat), perirenal, mammary and retroperitoneal fat from birth to early infancy in the face of adequate nutrition. Metabolic abnormalities noticed are: severe insulin resistance, hyperglycemia, diabetes mellitus, dyslipidemia (especially hypertriglyceridemia and low HDL), and leptin deficiency. Because of the relative paucity of adipose tissue, triglycerides accumulate excessively in multiple ectopic locations, most notably in the liver, skin, arterial wall, and in the muscles explaining most of the severe clinical complications: hepatic steatosis and cirrhosis, insulin resistance, hyperinsulinemia, diabetes, acanthosis nigricans, and arteriosclerosis.[1-4] As a direct consequence of the absence of subcutaneous adipocytes, circulating levels of leptin are nearly undetectable in children with BSCL.[4] Patients with the early-onset hyperinsulinemia in combination with congenital generalized lipodystrophy develop acromegaloid features (large hands, feet, and jaw), hypertrichosis, soft tissue hyperplasia, and somatomegaly.[12] Index child had all these features. Other associated anomalies include hypertropic cardiomyopathy, hypertropic pyloric stenosis and hydrocephalus, which were not noticed in our child.[25] Acanthosis nigricans is generally associated with severe metabolic derangements, which was not evident in our child.[12] Though metabolic abnormalities of hyperinsulinemia and insulin resistance are evident early in life, overt diabetes generally develops by second decade or adulthood.[25-7] In a report by Shirwalkar et al., though insulin resistance was noted at 9 months of life, overt diabetes mellitus was diagnosed only by 13 years.[3] In another report by Mandal et al., 3 children (3 year twins and 6 year) have not developed diabetes so far.[5] In a Brazilian study, among eight children with BSCL between 3 months and 19 years, two female patients were diagnosed with diabetes. However, age of onset of diabetes is not mentioned.[6] Similarly a child diagnosed at 4 months of age, developed diabetes at the age of 15 years.[7] Unusual feature in our child being development of diabetes mellitus at very early age of 5 months and there is only one report of overt diabetes mellitus described at 4 months.[8] Generally diabetes is difficult to control because of inherent insulin resistance and will require very high doses of insulin though presently our child is doing well with minimal insulin. Patients with triglyceride levels greater than 1000 mg/dl are also at risk of developing recurrent pancreatitis, predisposition for coronary artery disease, cerebro-vascular accidents, and cutaneous xanthomata. Our child developed stroke at 8 months of age, which could be attributed to hyperlipedemia, which again has not been described at this age. Low fat diet, medium chain triglycerides, polyunsaturated fats, and statins may help to bring down triglyceride levels.[12] Newer promising modalities of treatment include leptin therapy. Several small studies in patients with generalized lipodystrophy and familial partial lipodystrophy have shown that recombinant human leptin replacement improves metabolic abnormalities, reduces hyperglycemia, hyperlipidemia, insulin resistance, fatty infiltration of the liver, and hypermetabolism.[2] One intriguing experimental therapy in animals is transplantation of white fat into mice with severe lipoatrophy, which ameliorated the diabetes. Death occurs mostly in the third decade of life from cirrhosis and its complications, diabetic complications, and hypertrophic cardiomyopathy.[8] Our child had both clinical and metabolic features consistent with the diagnosis of Berardinelli Seip syndrome. Though Berardinelli Seip syndrome has been described in infancy,[357910] additional and unusual features such as overt diabetes mellitus at 5 months and stroke at 8 months of age prompted us to report this case. To the best of our knowledge, this is the second reported case of BSCL with overt diabetes mellitus at 5 months and first reported case of BSCL with stroke at 8 months of age.
  10 in total

Review 1.  Acquired and inherited lipodystrophies.

Authors:  Abhimanyu Garg
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

2.  Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy.

Authors:  Jacques Beltrand; Marta Beregszaszi; Didier Chevenne; Guy Sebag; Marc De Kerdanet; Frédéric Huet; Michel Polak; Nadia Tubiana-Rufi; Didier Lacombe; Alex M De Paoli; Claire Levy-Marchal
Journal:  Pediatrics       Date:  2007-08       Impact factor: 7.124

3.  Congenital generalized lipodystrophy in a 4 year old Chinese girl.

Authors:  Guanping Dong; Li Liang; Chaochun Zou
Journal:  Indian Pediatr       Date:  2005-10       Impact factor: 1.411

4.  Berardinelli-Seip congenital lipodystrophy.

Authors:  Kausik Mandal; S Aneja; A Seth; Anamita Khan
Journal:  Indian Pediatr       Date:  2006-05       Impact factor: 1.411

5.  Congenital generalized lipodystrophy in a 4-month-old infant.

Authors:  I H Lee; H L Chen; Y M Jeng; M T Cheng; L Y Tsao; M H Chang
Journal:  J Formos Med Assoc       Date:  2001-09       Impact factor: 3.282

6.  Severe cardiac phenotype of Berardinelli-Seip congenital lipodystrophy in an infant with homozygous E189X BSCL2 mutation.

Authors:  B Friguls; W Coroleu; R del Alcazar; P Hilbert; L Van Maldergem; G Pintos-Morell
Journal:  Eur J Med Genet       Date:  2008-11-12       Impact factor: 2.708

7.  Congenital generalized lipodystrophy in an Indian patient with a novel mutation in BSCL2 gene.

Authors:  H U Shirwalkar; Z M Patel; J Magre; P Hilbert; L Van Maldergem; R R Mukhopadhyay; A Maitra
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

8.  Two Japanese infants with congenital generalized lipodystrophy due to BSCL2 mutations.

Authors:  Atsushi Nishiyama; Mariko Yagi; Hiroyuki Awano; Yo Okizuka; Taro Maeda; Shinsaku Yoshida; Yasuhiro Takeshima; Masafumi Matsuo
Journal:  Pediatr Int       Date:  2009-03-31       Impact factor: 1.524

9.  Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy.

Authors:  L Van Maldergem; J Magré; T E Khallouf; T Gedde-Dahl; M Delépine; O Trygstad; E Seemanova; T Stephenson; C S Albott; F Bonnici; V R Panz; J L Medina; P Bogalho; F Huet; S Savasta; A Verloes; J J Robert; H Loret; M De Kerdanet; N Tubiana-Rufi; A Mégarbané; J Maassen; M Polak; D Lacombe; C R Kahn; E L Silveira; F H D'Abronzo; F Grigorescu; M Lathrop; J Capeau; S O'Rahilly
Journal:  J Med Genet       Date:  2002-10       Impact factor: 6.318

10.  [Congenital generalized lipodystrophy].

Authors:  Paulo P Figueiredo Filho; Alexandre Costa Val; Rosângela Diamante; Cristiane F Cunha; Rocksane C Norton; Joel A Lamounier; Ennio Leão
Journal:  J Pediatr (Rio J)       Date:  2004 Jul-Aug       Impact factor: 2.197

  10 in total
  3 in total

Review 1.  Congenital generalized lipodystrophies--new insights into metabolic dysfunction.

Authors:  Nivedita Patni; Abhimanyu Garg
Journal:  Nat Rev Endocrinol       Date:  2015-08-04       Impact factor: 43.330

2.  The neonatal onset diabetes mellitus of Chinese neonate with congenital generalized lipodystrophy 2: a case report.

Authors:  Yuan Yang; Li Ma; Jingjing Sun; Xiaohui Gong; Cheng Cai; Wenchao Hong
Journal:  BMC Endocr Disord       Date:  2022-03-29       Impact factor: 2.763

3.  Clinical and Mutational Features of Three Chinese Children with Congenital Generalized Lipodystrophy.

Authors:  Xueying Su; Ruizhu Lin; Yonglan Huang; Huiying Sheng; Xiaofei Li; Tzer Hwu Ting; Li Liu; Xiuzhen Li
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-09-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.